Is Biogen Stock a Buy Now?
Moving new medicines to the market can sometimes make biopharmaceutical companies tons of returns. Biogen (NASDAQ: BIIB) just scored a major new drug approval for an Alzheimer's disease therapy, so investors are understandably rushing to evaluate whether to buy the stock.
But the savviest investors are likely reluctant to dive in, even if things are looking better for the company than they have in recent history. Here's why.
One key factor that could drive Biogen's outperformance in the next few years is the launch of a new neurology medicine.
Source Fool.com
